Literature DB >> 15780054

Osteoprotegerin and RANKL in alcoholic liver cirrhosis.

Emilio Fábrega1, Aitor Orive, Covadonga García-Suarez, Maite García-Unzueta, Jose Antonio Amado, Fernando Pons-Romero.   

Abstract

BACKGROUND/AIMS: The mechanisms leading to osteoporosis in alcoholic liver disease remain poorly understood. Recently identified soluble circulating osteoprotegerin (OPG), is the osteoclastogenesis inhibitory factor. It acts as a decoy receptor for osteoclast activating factor, receptor activator of nuclear factor-kappaB ligand (RANKL), and impairs osteoclast function. The aim of our study was to investigate the OPG/RANKL system in alcoholic cirrhotic patients and their correlation with biochemical marker of bone turnover. PATIENTS AND METHODS: Serum OPG, RANKL, osteocalcin (OC), C-terminal cross-linking telopeptide of type I collagen (CTX-I), bone alkaline phosphatase activity (bALP), and urinary hydroxyproline were measured in 30 patients with alcoholic cirrhosis, and in 20 age- and sex-matched healthy controls.
RESULTS: OPG levels were significantly increased in patients with alcoholic cirrhosis compared with healthy subjects (5.9 pmol/l, range 2.7-9.0 vs 4.1 pmol/l, range 1.2-6.6; P < 0.001). RANKL levels were significantly higher in patients with cirrhosis (0.48 pmol/l, range 0.01-1.34) than in healthy subjects (0.11 pmol/l, range 0.01-0.90). There was a positive correlation between serum OPG and RANKL (r = 0.37; P < 0.001), bALP (r = 0.66; P < 0.001) and urinary hydroxyproline (r = 0.51; P < 0.05) but not with OC and CTX-I.
CONCLUSIONS: OPG might partly represent a compensating mechanism to the negative balance of bone remodelling in patients with alcoholic cirrhosis. Copyright Blackwell Munksgaard 2005

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780054     DOI: 10.1111/j.1478-3231.2005.01073.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  17 in total

1.  Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.

Authors:  Xinqiang Huang; Hong Cai; Ron Ammar; Yan Zhang; Yihe Wang; Kandasamy Ravi; John Thompson; Gabor Jarai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-08       Impact factor: 4.052

Review 2.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 3.  Vitamin D deficiency in chronic liver disease.

Authors:  Paula Iruzubieta; Álvaro Terán; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2014-12-27

Review 4.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

5.  Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.

Authors:  Sittisak Honsawek; Tawatchai Chaiwatanarat; Paisarn Vejchapipat; Voranush Chongsrisawat; Nutchanart Thawornsuk; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2009-01-29       Impact factor: 1.827

Review 6.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

7.  High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue.

Authors:  Núria Guañabens; Anna Enjuanes; Luisa Alvarez; Pilar Peris; Llorenç Caballería; M Jesús Martínez de Osaba; Dacia Cerdá; Anna Monegal; Francesca Pons; Albert Parés
Journal:  J Bone Miner Metab       Date:  2009-02-20       Impact factor: 2.626

8.  Alcohol and bone.

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2014-01-30

Review 9.  Cellular and molecular mechanisms of alcohol-induced osteopenia.

Authors:  Zhenhua Luo; Yao Liu; Yitong Liu; Hui Chen; Songtao Shi; Yi Liu
Journal:  Cell Mol Life Sci       Date:  2017-07-03       Impact factor: 9.261

Review 10.  Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations.

Authors:  Alexander J Kovalic; George Cholankeril; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.